A new highly sensitive test has found 10 per cent of milk samples contain low levels of the pathogen, according...
Actiphage is a new diagnostic from PBD Biotech that provides a rapid, highly specific and sensitive assay for the cost-effective detection of live mycobacteria in blood and milk.
Mycobacteria are the cause of a number of diseases in cattle and other species, such as bovine TB and Johne’s disease, which not only affect animal health but have a significant economic impact on the dairy industry. Hence the need for regular blood and milk testing, to detect, monitor and manage herd-level infection.
Bulk milk testing with Actiphage can detect 1-2 cells in 50ml of milk providing a high level of confidence in the quality of milk. Results are available in hours enabling the rapid detection and identification of infected herds and individuals.
A survey* of retail purchased semi-skimmed pasteurised milk for MAP showed that 10% contained viable cells, showing it can evade pasteurisation.
Actiphage has been successfully used to detect live mycobacteria in raw milk, pasteurised milk, powdered infant formula, cheese and in the blood of infected animals.
International trials of Actiphage are underway.
PBD Biotech provides a bulk milk testing service for MAP. Contact us to find out more.
PBD Biotech has announced that is focusing its efforts on developing Actiphage as a rapid blood test for Human Tuberculosis (TB) and will be suspending its commercial Johne’s Testing in blood and MAP testing in bulk milk service (from January 2023) More information.
Please contact us if you would like to discuss this further.
Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom
More reasons to invest in better diagnostics for #tuberculosis 1.6 million preventable deaths and increased pressure on the few treatments available. #EndTB
Read MoreDelighted Dr Marie Roskrow is the new Chair @PBDBiotech to support development of our rapid TB diagnostic. A physician-scientist she brings expertise from @KinomicaLtd @ImevaX along with Patrys Limited, METALINEAR LIMITED, ArcticZymes Technologies
Read MoreTesting 4 tuberculosis gained renewed attention in 2022 reports @360DxNews Highlighting $30m funding @UNITAID for @FINDdx also @PBDBiotech gaining $2.9M for its blood-based test to predict which individuals with latent TB will progress to active disease
Read More